|WILMINGTON, Del. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 8, 2018--
Incyte Corporation (NASDAQ:INCY) and Syros Pharmaceuticals, Inc.
(NASDAQ:SYRS) announced today that the companies have entered into a
target discovery, research collaboration and option agreement. Under the
agreement, Syros will use its proprietary gene control platform to
identify novel therapeutic targets with a focus in myeloproliferative
neoplasms (MPNs), and Incyte will receive... |